Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.

ABSTRACT:

Background

Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non-Small Cell Lung Cancer Patients.

Methods

Data from a controlled clinical trial evaluating the effect of CIMAvax-EGF were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive caus

SUBMITTER: Lorenzo-Luaces P 

PROVIDER: S-EPMC7433036 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature